- $10.50bn
- $9.59bn
- $570.40m
- 100
- 15
- 92
- 79
Annual income statement for Doximity, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 207 | 344 | 419 | 475 | 570 |
Cost of Revenue | |||||
Gross Profit | 176 | 304 | 366 | 425 | 515 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 154 | 230 | 294 | 312 | 343 |
Operating Profit | 53.3 | 114 | 125 | 164 | 228 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 57.8 | 114 | 133 | 185 | 264 |
Provision for Income Taxes | |||||
Net Income After Taxes | 50.2 | 155 | 113 | 148 | 223 |
Net Income Before Extraordinary Items | |||||
Net Income | 50.2 | 155 | 113 | 148 | 223 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 21.6 | 133 | 113 | 148 | 223 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.121 | 0.698 | 0.529 | 0.748 | 1.12 |